Clinical observation of cyberknife therapy combined with TS-1 in treatment of local advanced pancreatic cancer / 解放军医学杂志

ABSTRACT

Objective To evaluate the effect and toxicity of cyberknife therapy combined with titanium silicalite-1 (TS-1) in treatment of local advanced pancreatic cancer (LAPC). Methods Ninety-five patients with LAPC were divided into two groups cyberknife group (control group, n=45) received cyberknife therapy only, and combination group (n=50) received cyberknife therapy combined with TS-1. The adjuvant chemotherapy was performed 3 weeks after radiotherapy, and lasted for 4-6 cycles continuously. The effect, side effect, progression-free survival (PFS) and overall survival (OS) were recorded. Results In cyberknife group and combination group, the objective response rates (ORR, CR+PR) were 75.6% and 86.0% (P0.05) respectively. The indexes of total bilirubin and CA19-9 were significantly improved in the both groups after than before treatment with statistical significance (P0.05). In the median follow-up time of 20 months, the median PFS was 10.1 and 11.2 months and the median OS was 15.5 and 16.7 months in cyberknife and combination group, respectively (P>0.05). The incidences of digestive tract adverse reaction and myelosuppression in cyberknife group and combination group were 48.9% and 56.0%, 11.1% and 20.0%, respectively (P>0.05). There was no grade 3-4 serious adverse reaction. Conclusion Cyberknife combined with TS-1 is effective and safe for patients with LAPC, may improve local control rate, effective rate, PFS and OS.